NCT05159700
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05159700
Title A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Zhuhai Yufan Biotechnologies Co., Ltd
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Sarah Cannon Research Institute at HealthONE Denver Colorado 80218 United States Details
Sarah Cannon Research Institute at Florida Cancer Specialists Orlando Florida 32827 United States Details
Christ Hospital Cincinnati Ohio 21073 United States Details
NEXT Oncology Austin Texas 73301 United States Details
Mays Cancer Center San Antonio Texas 78229 United States Details
NEXT Oncology Fairfax Virginia 22031 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field